Consensus Inovio Pharmaceuticals, Inc.

Equities

INO

US45773H4092

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
9.68 ^USD	-5.10%		-12.24%	+58.17%

Apr. 16	Powell Comments, Middle East Tensions in Focus as US Equity Futures Gain Pre-Bell	MT
Apr. 16	Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	MT

Evolution of the average Target Price on Inovio Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f7f.4grehX17GyTdzo1CS7CIT4QwwcNFEM6MOWn4ntOGuuI.iXuK4h9LUE-CucAoJMe4I9wGuIEDdKPeVwy074mr-4HTXrG0FhV_cpuU_g~60f957a8b1de48fb1e3aed12d2665140

Analyst Recommendations on Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals Shares Slump Pre-Bell After Pricing of $36 Million Offering of Common Stock, Warrants	Apr. 16	MT
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target	Jan. 25	MT
RBC Trims Price Target on Inovio Pharmaceuticals to $2 From $3, Maintains Sector Perform Rating, Speculative Risk Qualifier	23-03-02	MT
Maxim Downgraded Inovio Pharmaceuticals to Hold From Buy	22-11-09	MT
BofA Securities Downgrades Inovio Pharmaceuticals to Underperform From Neutral With $2 Price Target	22-11-01	MT
Maxim Lowers Price Target for Inovio Pharmaceuticals to $5 From $11, Maintains Buy Rating	22-08-10	MT
RBC Reinstates Inovio Pharmaceuticals at Sector Perform-Speculative Risk, Assigns $4 Price Target, Awaiting 'More Attractive' Entry Point, 'Clearer Path for Value Creation'	22-07-19	MT
Oppenheimer Downgrades Inovio Pharmaceuticals to Perform From Outperform, Removes $30 Price Target	22-05-11	MT
RBC Cuts Price Target on Inovio Pharmaceuticals to $5 From $6, Maintains Sector Perform-Speculative Risk Rating	22-03-02	MT
Maxim Group Adjusts Inovio Pharmaceuticals Price Target to $11 From $20, Maintains Buy Rating	22-02-02	MT
BofA Securities Upgrades Inovio Pharmaceuticals to Neutral From Underperform, Adjusts Price Target to $10 From $8	22-01-21	MT
Jefferies Assumes Inovio Pharmaceuticals at Hold, $6 Price Target	21-12-29	MT
INOVIO PHARMACEUTICALS : BofA Securities Downgrades Inovio Pharmaceuticals to Underperform From Neutral, Sets $8 Price Target	21-09-10	MT
INOVIO PHARMACEUTICALS : Jefferies Starts Inovio Pharmaceuticals at Hold With $9 Price Target	21-06-24	MT
INOVIO PHARMACEUTICALS : RBC Reduces Price Target on Inovio Pharmaceuticals to $7 From $8, Maintains Sector Perform, Speculative Risk	21-05-11	MT
INOVIO PHARMACEUTICALS : BofA Securities Initiates Coverage on Inovio Pharmaceuticals With Neutral Rating, $13 Price Target	21-03-23	MT
INOVIO PHARMACEUTICALS : Oppenheimer Starts Inovio Pharmaceuticals at Outperform With $35 Price Target	21-02-12	MT
INOVIO PHARMACEUTICALS : Roth Capital Downgrades Inovio Pharmaceuticals Back to Sell From Neutral; Price Target Remains $8	20-11-17	MT
INOVIO PHARMACEUTICALS : Roth Capital Upgrades Inovio Pharmaceuticals to Neutral From Sell; Price Target is $8	20-11-10	MT
INOVIO PHARMACEUTICALS : RBC Capital Adjusts Inovio Pharmaceuticals PT to $11 From $12, Maintains Sector Perform - Speculative Risk	20-11-10	MT
Inovio Pharmaceuticals, Inc.'s HIV Vaccine Elicits Nearly 100% Immune Response Rates in Clinical Study	17-05-24	CI